Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-002901-37
    Sponsor's Protocol Code Number:251AD201
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2018-01-04
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2017-002901-37
    A.3Full title of the trial
    Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer’s Disease or with Mild Alzheimer’s Disease.
    Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la seguridad, tolerabilidad y eficacia de BIIB092 en sujetos con deterioro cognitivo leve debido a enfermedad de Alzheimer o con enfermedad de Alzheimer leve.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
    Estudio de Fase II de BIIB092 en sujetos con enfermedad de Alzheimer (EA) leve.
    A.4.1Sponsor's protocol code number251AD201
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT03352557
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBiogen Idec Research Limited
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBiogen Idec Research Limited
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBiogen Idec Research Limited
    B.5.2Functional name of contact pointBiogen España
    B.5.3 Address:
    B.5.3.1Street AddressPaseo de la Castellana, 41
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28046
    B.5.3.4CountrySpain
    B.5.4Telephone number0034913107110
    B.5.5Fax number0034913107181
    B.5.6E-mailclinicaltrials@biogenidec.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code BIIB092
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot yet available
    D.3.9.2Current sponsor codeBIIB092
    D.3.9.3Other descriptive nameBMS986168
    D.3.9.4EV Substance CodeSUB186860
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeHumanized monoclonal antibody
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) or mild AD.
    Deterioro cognitivo leve (DCL) debido a enfermedad de Alzheimer (EA) o EA leve.
    E.1.1.1Medical condition in easily understood language
    Alzheimer’s disease
    Enfermedad de Alzheimer
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10001896
    E.1.2Term Alzheimer's disease
    E.1.2System Organ Class 100000004852
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the safety and tolerability of BIIB092 in subjects with MCI due to AD or with mild AD
    Evaluar la seguridad y la tolerabilidad de BIIB092 en sujetos con DCL debido a EA o con EA leve.
    E.2.2Secondary objectives of the trial
    To evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and functional impairment in subjects with MCI due to AD or with mild AD.

    To evaluate the immunogenicity of BIIB092 after multiple doses in subjects with MCI due to AD or with mild AD.
    Evaluar la eficacia de múltiples dosis de BIIB092 para ralentizar el deterioro cognitivo y funcional en sujetos con DCL debido a EA o con EA leve.

    Evaluar la inmunogenicidad de BIIB092 después de múltiples dosis en sujetos con DCL debido a EA o con EA leve.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Inclusion Criteria:
    • Must have a gradual and progressive change in memory function over more than 6 months.
    • Must meet all of the clinical criteria for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) or mild AD and must have
    o Objective evidence of cognitive impairment at Screening
    o Clinical Dementia Rating Scale (CDR) global score of 0.5 for MCI due to AD or 0.5 or 1 for mild AD
    o Mini-Mental State Examination (MMSE) score of 22 to 30 (inclusive)
    o CDR Memory Box score of ≥0.5
    • Must consent to apolipoprotein E (ApoE) genotyping
    • Must have 1 informant/study partner
    • Must have amyloid beta positivity confirmed at Screening
    Criterios de inclusión:
    • Tener un cambio gradual y progresivo en la función de memoria durante más de 6 meses
    • Cumplir todos los criterios clínicos de deterioro cognitivo leve (DCL) debido a la enfermedad de Alzheimer (EA) o EA leve y tener
    o Signos objetivos de deterioro cognitivo en la selección
    o Puntuación en la escala de evaluación de la demencia clínica (Clinical Dementia Rating, CDR) de 0,5 para el DCL debido a la EA o de 0,5 o 1 para la EA leve
    o Puntuación en el miniexamen cognoscitivo (Mini-Mental State Examination, MMSE) de 22 a 30 (ambos inclusive)
    o Puntuación del apartado de memoria de CDR de ≥0,5
    • Proporcionar el consentimiento para la genotipificación de la apolipoproteína E (ApoE)
    • Tener 1 informante o acompañante del estudio
    • Tener un resultado positivo confirmado para beta amiloide en la selección
    E.4Principal exclusion criteria
    Key Exclusion Criteria:
    • Any medical or neurological/neurodegenerative condition (other than AD) that, in the opinion of the Investigator, might be a contributing cause to the participant’s cognitive impairment or could lead to discontinuation, lack of compliance, interference with study assessments, or safety concerns
    • Clinically significant, unstable psychiatric illness
    • Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year
    • Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities
    • History of unstable angina, myocardial infarction, chronic heart failure or clinically significant conduction abnormalities within 1 year prior to Screening Visit 1
    • Indication of impaired renal or liver function
    • Alcohol or substance abuse in past 1 year
    • Clinically significant systemic illness or serious infection within 30 days prior to or during the screening period
    • Use of allowed medications for chronic conditions at doses that have not been stable for at least 4 weeks prior to Screening Visit 1, or use of AD medications at doses that have not been stable for at least 8 weeks prior to Screening Visit 1.
    • Use of any medications that, in the opinion of the Investigator, may contribute to cognitive impairment, put the participants at higher risk for adverse events (AEs), or impair the participant’s ability to perform cognitive testing or complete study procedures.
    • Contraindications to study procedures

    NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
    Criterios de exclusión principales:
    • Cualquier afección médica o neurológica/neurodegenerativa (aparte de la EA) que, en opinión del investigador, pudiera ser una causa que contribuya al deterioro cognitivo del participante o que pudiera causar la interrupción del tratamiento, falta de cumplimiento terapéutico, interferencias con las evaluaciones del estudio o preocupaciones relacionadas con la seguridad
    • Enfermedad psiquiátrica inestable clínicamente significativa
    • Haber padecido un accidente cerebrovascular o un accidente isquémico transitorio (AIT) o una pérdida inexplicable de la consciencia en el último año
    • Hemorragia cerebral, trastorno hemorrágico y anomalías cerebrovasculares importantes
    • Antecedentes de angina inestable, infarto de miocardio, insuficiencia cardíaca crónica o anomalías de la conducción clínicamente significativas en el último año antes de la visita 1 de selección
    • Indicación de insuficiencia renal o hepática
    • Abuso de alcohol o drogas en el último año
    • Enfermedad sistémica o infección grave clínicamente significativas en los 30 días previos o durante el periodo de selección
    • Uso de medicamentos permitidos para afecciones crónicas a dosis que no han sido estables durante al menos 4 semanas antes de la visita 1 de selección, o uso de medicamentos para la EA a dosis que no han sido estables durante al menos 8 semanas antes de la visita 1 de selección
    • Uso de cualquier medicamento que, en opinión del investigador, pueda contribuir al deterioro cognitivo, ponga al participante en un mayor riesgo de sufrir acontecimientos adversos (AA), o afectar a la capacidad del participante para realizar las pruebas cognitivas o los procedimientos del estudio
    • Contraindicaciones para los procedimientos del estudio

    NOTA: Podrán aplicarse otros criterios de inclusión/exclusión definidos en el protocolo.
    E.5 End points
    E.5.1Primary end point(s)
    • Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
    AEs: any sign, symptom, or diagnosis/disease that is unfavorable or unintended, that is new, or if pre-existing, worsens in participants administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. SAEs: an event that results in death; an event that, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event); an outcome that results in a congenital anomaly/birth defect diagnosed in a child of a participant; an event that requires or prolongs inpatient hospitalization; an event that results in persistent or significant disability/incapacity. Any other medically important event that, in the opinion of the investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.
    • Percentage of Participants With Abnormal Laboratory Safety Assessments
    • Percentage of Participants With Changes From Baseline Over Time in Laboratory Safety Assessments
    • Percentage of Participants With Abnormal Vital Signs
    • Percentage of Participants With Changes From Baseline Over Time in Vital Signs
    • Percentage of Participants With Abnormal 12-Lead Electrocardiogram (ECG) Assessments
    • Percentage of Participants With Changes From Baseline in Over Time in 12-Lead Electrocardiogram (ECG) Assessments
    • Percentage of Participants With Changes in Physical Examinations Assessments
    • Porcentaje de participantes con acontecimientos adversos (AA) y acontecimientos adversos graves (AAG)
    AA: cualquier signo, síntoma o diagnóstico/enfermedad que sea desfavorable o no intencionado, que sea nuevo o, si existía previamente, que empeore en los participantes a los que se administró un producto farmacéutico y que no tiene necesariamente una relación causal con este tratamiento. AAG: acontecimiento que tiene como consecuencia la muerte; acontecimiento que, en opinión del investigador, pone al participante en riesgo inmediato de muerte (acontecimiento potencialmente mortal); desenlace que tiene como consecuencia una anomalía congénita/defecto de nacimiento en el hijo de un participante; acontecimiento que requiere o prolonga la hospitalización; acontecimiento que tiene como consecuencia una discapacidad/incapacidad persistente o significativa. Cualquier otro acontecimiento importante desde el punto de vista médico que, en opinión del investigador, puede poner en peligro al participante o requerir una intervención para evitar alguno de los desenlaces enumerados en la definición anterior.
    • Porcentaje de participantes con resultados anómalos en las evaluaciones analíticas de la seguridad
    • Porcentaje de participantes con cambios con el tiempo respecto al inicio del estudio en las evaluaciones analíticas de la seguridad
    • Porcentaje de participantes con anomalías en las constantes vitales
    • Porcentaje de participantes con cambios con el tiempo respecto al inicio del estudio en las constantes vitales
    • Porcentaje de participantes con resultados anómalos en las evaluaciones del electrocardiograma (ECG) de 12 derivaciones
    • Porcentaje de participantes con cambios con el tiempo respecto al inicio del estudio en las evaluaciones del electrocardiograma (ECG) de 12 derivaciones
    • Porcentaje de participantes con cambios en las evaluaciones mediante exploraciones físicas
    E.5.1.1Timepoint(s) of evaluation of this end point
    Up to week 90
    Hasta la Semana 90
    E.5.2Secondary end point(s)
    • Change From Baseline Over Time at Week 78 on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
    • Percentage of Participants With Anti-BIIB092 Antibodies in Serum Over Time up to Week 90
    - Medición del cambio desde el inicio hasta la semana 78 en la suma de recuadros de la escala de evaluación de la demencia clínica (CDR).
    - Porcentaje de sujetos con anticuerpos anti-BIIB092 en suero con el paso del tiempo hasta la semana 90.
    E.5.2.1Timepoint(s) of evaluation of this end point
    • For CDR-SB the timeframe is up to week 78
    • For participants with Anti-BIIB092 Abs, the time frame is up to week 90
    • Para el CDR Basal el plazo es hasta la Semana 78
    • Para los sujetos con anticuerpos Anti-BIIB092, el plazo es hasta la semana 90.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Evaluation of biomarkers for AD
    Evaluacion de Biomarcadores para EA
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA37
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    France
    Germany
    Italy
    Japan
    Poland
    Spain
    Sweden
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita del último paciente.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 232
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 292
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    At the start of the study, participants must be capable of giving consent personally, however, as study progress participants might need legal representative to provide consent
    Al inicio del estudio los sujetos deben ser capaces de otorgar su consentimiento, aunque, durante el desarrollo del ensayo, los sujetos pueden necesitar un representante legal para consentir.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state35
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 130
    F.4.2.2In the whole clinical trial 528
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    No further provisions are made for access to the study treatment, unless the subject elects to
    enter an extension study following the Week 78 Visit (to be initiated at the Sponsor’s discretion).
    No se preve acceso al medicamento del estudio, al no ser que el paciente quiera participar en el estudio de extensión tras la visita de la semana 78 (se iniciará cuando así lo decida el promotor).
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-02-06
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-01-10
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2021-05-17
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 20 12:32:58 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA